Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Moodys
Johnson and Johnson
McKesson
Medtronic

Last Updated: December 6, 2022

Details for New Drug Application (NDA): 022181


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 022181 describes KUVAN, which is a drug marketed by Biomarin Pharm and is included in two NDAs. It is available from two suppliers. There are ten patents protecting this drug and three Paragraph IV challenges. Additional details are available on the KUVAN profile page.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the sapropterin dihydrochloride profile page.
Summary for 022181
Tradename:KUVAN
Applicant:Biomarin Pharm
Ingredient:sapropterin dihydrochloride
Patents:9
Pharmacology for NDA: 022181
Mechanism of ActionBreast Cancer Resistance Protein Inhibitors
P-Glycoprotein Inhibitors
Phenylalanine Hydroxylase Activators
Suppliers and Packaging for NDA: 022181
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KUVAN sapropterin dihydrochloride TABLET;ORAL 022181 NDA Dr. Reddys Laboratories Inc. 43598-749 43598-749-04 1 BOTTLE in 1 CARTON (43598-749-04) > 120 TABLET in 1 BOTTLE
KUVAN sapropterin dihydrochloride TABLET;ORAL 022181 NDA BioMarin Pharmaceutical Inc. 68135-300 68135-300-02 120 TABLET in 1 BOTTLE (68135-300-02)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Dec 13, 2007TE:ABRLD:Yes
Patent:See Plans and PricingPatent Expiration:May 16, 2026Product Flag?Substance Flag?Delist Request?Y
Patent:See Plans and PricingPatent Expiration:May 17, 2025Product Flag?Substance Flag?Delist Request?Y
Patent:See Plans and PricingPatent Expiration:May 17, 2025Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Mallinckrodt
McKesson
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2022 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
 NCE-1 Patent Challenge Dates 2022 - 2023
 ClinicalTrialExchange - Connecting volunteers and trials
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group